deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07246590

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) (COVE-2)

COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

Sponsor: Allucent (US) LLC

Conditions Common Warts Common Warts (Verruca Vulgaris) Human Papilloma Virus (HPV) Warts
Interventions VP-102 Vehicle
Updated 2 times since 2025 Last updated: Jan 19, 2026 Started: Dec 17, 2025 Primary completion: Jun 30, 2027 Completion: Jun 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Common Warts and Common Warts (Verruca Vulgaris) and is currently actively recruiting participants. Allucent (US) LLC leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  2. Dec 2025 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Allucent (US) LLC
  • Canfield Scientific Inc.
  • Medidata Solutions
  • Myonex LLC
  • Torii Pharmaceutical Co. Ltd.
  • Veeva Systems
  • Verrica Pharmaceuticals Inc.
Data source: Verrica Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations